| The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58 O Mosenzon, SD Wiviott, HJL Heerspink, JP Dwyer, A Cahn, EL Goodrich, ... Diabetes Care 44 (8), 1805-1815, 2021 | 69 | 2021 |
| Total and proteinase K-resistant α-synuclein levels in erythrocytes, determined by their ability to bind phospholipids, associate with Parkinson’s disease S Abd-Elhadi, A Honig, D Simhi-Haham, M Schechter, E Linetsky, ... Scientific reports 5 (1), 11120, 2015 | 59 | 2015 |
| α-Synuclein translocates to the nucleus to activate retinoic-acid-dependent gene transcription D Davidi, M Schechter, S Abd Elhadi, A Matatov, L Nathanson, R Sharon IScience 23 (3), 2020 | 44 | 2020 |
| From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes O Mosenzon, S Del Prato, M Schechter, LA Leiter, A Ceriello, ... Cardiovascular diabetology 20 (1), 92, 2021 | 42 | 2021 |
| α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4, 5-bisphosphate M Schechter, M Atias, S Abd Elhadi, D Davidi, D Gitler, R Sharon Journal of Biological Chemistry 295 (52), 18076-18090, 2020 | 33 | 2020 |
| Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial O Mosenzon, I Raz, SD Wiviott, M Schechter, EL Goodrich, I Yanuv, ... Diabetes Care 45 (10), 2350-2359, 2022 | 30 | 2022 |
| A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease M Schechter, J Grigoletto, S Abd-Elhadi, H Glickstein, A Friedman, ... Molecular neurodegeneration 15, 1-21, 2020 | 27 | 2020 |
| Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS A Koshino, M Schechter, T Sen, P Vart, BL Neuen, B Neal, C Arnott, ... Diabetes Care 45 (11), 2644-2652, 2022 | 21 | 2022 |
| Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence M Schechter, C Melzer-Cohen, A Rozenberg, I Yanuv, G Chodick, ... Cardiovascular Diabetology 20, 1-12, 2021 | 20 | 2021 |
| Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults M Schechter, C Melzer Cohen, I Yanuv, A Rozenberg, G Chodick, ... Cardiovascular Diabetology 21 (1), 104, 2022 | 15 | 2022 |
| Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial M Schechter, SD Wiviott, I Raz, EL Goodrich, A Rozenberg, I Yanuv, ... The Lancet Diabetes & Endocrinology 11 (4), 233-241, 2023 | 12 | 2023 |
| Dapagliflozin and anemia in patients with chronic kidney disease A Koshino, M Schechter, GM Chertow, P Vart, N Jongs, RD Toto, ... NEJM evidence 2 (6), EVIDoa2300049, 2023 | 11 | 2023 |
| Effects of dapagliflozin on hospitalizations in patients with chronic kidney disease: a post hoc analysis of DAPA-CKD M Schechter, N Jongs, GM Chertow, O Mosenzon, JJV McMurray, ... Annals of internal medicine 176 (1), 59-66, 2023 | 11 | 2023 |
| Kidney outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes O Mosenzon, M Schechter, G Leibowitz Advances in Chronic Kidney Disease 28 (4), 347-360, 2021 | 9 | 2021 |
| Adolescent thyroid disorders and risk for type 2 diabetes in young adulthood A Bardugo, E Derazne, I Zucker, CD Bendor, G Puris, M Lutski, ... The Journal of Clinical Endocrinology & Metabolism 106 (9), e3426-e3435, 2021 | 7 | 2021 |
| Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty P Vart, JH Butt, N Jongs, M Schechter, GM Chertow, DC Wheeler, ... The Journals of Gerontology: Series A 79 (2), glad181, 2024 | 6 | 2024 |
| Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and … M Schechter, M Fischer, O Mosenzon Diabetes, Obesity and Metabolism 24 (6), 969-982, 2022 | 5 | 2022 |
| Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial M Schechter, G Leibowitz, O Mosenzon Annals of Translational Medicine 8 (24), 2020 | 5 | 2020 |
| Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic … KW Chan, JD Smeijer, M Schechter, N Jongs, P Vart, DE Kohan, ... Kidney International 104 (6), 1219-1226, 2023 | 4 | 2023 |
| Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence M Schechter, C Melzer Cohen, A Fishkin, A Rozenberg, I Yanuv, ... Cardiovascular Diabetology 22 (1), 126, 2023 | 4 | 2023 |
